Recent advances in trophoblast cell‐surface antigen 2 targeted therapy for solid tumors

Liao, Shutan; Wang, Bing; Zeng, Rong; Bao, Haifeng; Chen, Xiaomin; Dixit, Rakesh; Xing, Xiaoyan

doi:10.1002/ddr.21870

Cited by 22 publications

(14 citation statements)

References 115 publications

(131 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies have proved that trop2 is associated with tumor progression and the development of metastases ( Ripani et al, 1998 ; Bignotti et al, 2012 ; Trerotola et al, 2013 ). Trop2-targeted ADC drugs mainly include sacituzumab govitecan, PF-06664178, and datopotamab deruxtecan, of which sacituzumab govitecan and datopotamab deruxtecan have presented appealing clinical efficacy in solid cancers, while PF-06664178 has failed in a phase I trial ( Liao et al, 2021 ). The response rate of heavily pretreated metastatic triple-negative breast cancer patients who received sacituzumab govitecan-hziy was 33.3%, and the median overall survival was 13.0 months.…”

Section: Discussionmentioning

confidence: 99%

Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study

Liu

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Antibody-drug conjugate (ADC) is a promising therapy for solid cancer that has raised global concern. Although several papers have reviewed the current state of ADCs in different solid cancers, a quantitative analysis of the publications in this field is scarce.Methods: Publications related to ADC in the field of solid cancer were obtained from the Web of Science Core Collection. Data analyses were performed with VOSviewer 1.6.9, HistCite 2.1, CiteSpace V and R package Bibliometrix.Results: A total of 3,482 records were obtained in the holistic field and 1,197 in the clinical field. Steady growth in the number of publications was observed. The United States was the leading contributor in this field. Krop IE was the most influential author. The most productive institution was Genentech Inc., while Mem Sloan Kettering Canc Ctr was the most cited one. The most impactful journal was the Journal of Clinical Oncology. A total of 37 burst references and five burst references were identified between 2017–2022 in the holistic and clinical fields, respectively. Keywords analysis indicated that ADCs research mainly involved breast cancer, triple-negative breast cancer, ovarian cancer, small cell lung cancer, prostate cancer, gastric cancer, and urothelial carcinoma. ADC agents including trastuzumab emtansine, trastuzumab deruxtecan, sacituzumab govitecan, enfortumab vedotin, and rovalpituzumab tesirine were highly studied. Targets including HER2, trophoblast cell-surface antigen, mesothelin, delta-like ligand 3, and nectin-4 were the major concerns.Conclusion: This study analyzed publications concerning ADCs in the field of solid cancer with bibliometric analysis. Further clinical trials of ADCs and designs of the next generation of ADCs are the current focuses of the field. Acquired resistance of ADCs and biomarkers for ADC therapy efficacy monitoring are future concerns.

show abstract

Section: Discussionmentioning

confidence: 99%

Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study

Liu

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Trophoblasts are the main component of the placental structure and play an important role in the formation of the placenta and the maintenance of the normal development of the fetus. In the early stage of blastocyst implantation, trophectoderm cells differentiate into two types of trophoblast cells, namely cytotrophoblast cells and syncytial trophoblast cells ( 20 ). In the early stage of blastocyst implantation, trophectoderm cells differentiate into two types of trophoblast cells, namely cytotrophoblast cells and syncytial trophoblast cells.…”

Section: Discussionmentioning

confidence: 99%

The Mechanism of Downregulation of Twist1 Inhibiting Trophoblast Invasion and Aggravating the Development of Preeclampsia

Yang

Tong

2022

Front. Surg.

View full text Add to dashboard Cite

To study the expression of under expressed transcription factor Twist1 in preeclampsia (PE) and its effect on the invasion of placental trophoblast cells and to explore its related mechanism on the development of PE by establishing a pregnant rat model. Methods: the villi were collected from the induced abortion in the first trimester (6–8 weeks), the normal placenta (18–20 weeks) induced by the second trimester, the term placenta tissue of normal pregnancy (37–40 weeks), and the placental tissue of patients with PE, to detect the expression of Twist1. Trophoblast cells were subjected to primary culture in placental tissues of normal pregnant women and placental tissues of PE patients. The invasion ability of the two groups of trophoblasts was detected, and the primary cultured trophoblasts were divided into two groups: an experimental group and a control group. Specific Twist1 siRNA was added to the experimental group, and no reagents were added to the control group. The above-mentioned cells were given different interventions. To explore the effect of Twist1 on trophoblast cell invasion, cells were cultivated for 72 h. The SD rats were conceived. After the pregnancy was stable, the SD rats in different groups were treated with different treatments (interference with Twist1), and the average systolic blood pressure and urine protein of the gestational mothers in the different treatment groups were measured at 1 week, 2 weeks, and full-term pregnancy. The expression of Twist1 in the placenta tissue of SD rats with different interventions at full-term pregnancy was detected. The results showed that Twist1 expression is down-regulated in PE, and the invasion ability of placental trophoblast cells in PE patients is weak. After inhibiting Twist1, the mean tail artery pressure and urine protein level of SD pregnant rats increase, showing a trend of PE. The mechanism may be related to the inhibition of the placenta by Twist1 Trophoblast cell invasion.

show abstract

“…Varied studies have shown the involvement of Trop-2 in multiple growth-stimulating signaling pathways, thereby playing a role in the growth and proliferation of tumor cells. An increased expression level of Trop-2 is closely associated with a poor prognosis of various solid tumors [ 27 , 28 ]. Trop-2 has been selected as the prognostic marker or an attractive target to develop targeting molecules for diagnosis and tumor therapy.…”

Section: Discussionmentioning

confidence: 99%

Identification and Characterization of Specific Nanobodies against Trop-2 for Tumor Targeting

Wang

Lin

et al. 2022

IJMS

View full text Add to dashboard Cite

Trophoblast cell-surface antigen 2 (Trop-2) is a tumor-associated antigen that is connected with the development of various tumors and has been identified as a promising target for tumor immunotherapy. To date, the immunotherapy against Trop-2 mainly relies on the specific targeting by monoclonal antibody in antibody-drug conjugate (ADC). Alternatively, the single domain antibodies of nanobodies (Nbs) possesses unique properties such as smaller size, better tissue penetration, etc., to make them good candidates for tumor targeting. Thus, it was proposed to develop anti-Trop-2 Nbs for tumor targeting in this study. Generally, three consecutive rounds of bio-panning were performed against immobilized recombinant Trop-2, and yielded three Nbs (Nb60, Nb65, and Nb108). The affinity of selected Nbs was determined in the nanomolar range, especially the good properties of Nb60 were verified as a promising candidate for tumor labeling. The binding to native Trop-2 was confirmed by flow cytometry against tumor cells. The inhibitory effects of the selected Nbs on tumor cell proliferation and migration were confirmed by wound healing and Transwell assay. The clear localization of the selected Nbs on the surface of tumor cells verified the potent labeling efficiency. In conclusion, this study provided several Nbs with the potential to be developed as targeting moiety of drug conjugates.

show abstract

Recent advances in trophoblast cell‐surface antigen 2 targeted therapy for solid tumors

Cited by 22 publications

References 115 publications

Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study

Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study

The Mechanism of Downregulation of Twist1 Inhibiting Trophoblast Invasion and Aggravating the Development of Preeclampsia

Identification and Characterization of Specific Nanobodies against Trop-2 for Tumor Targeting

Contact Info

Product

Resources

About